BACKGROUND: Eighty percent of hypopharyngeal squamous cell carcinoma patients have advanced stages (III and IV) of the disease, and biological markers are required to predict high-risk head and neck squamous cell carcinoma patients in need of highly aggressive treatments after surgery to improve the survival rate. We analyzed the potential prognostic value of galectin 7 in a series of 81 stage IV hypopharyngeal SCCs because galectin 7 is an emerging marker involved in the epidermal development of pluristratified epithelia and in epidermal cell migration. METHODS: The immunohistochemical expression of galectin 7 was determined on a series of 81 stage IV hypopharyngeal SCCs and was compared with that of galectins 1 and 3. RESULTS: High levels of galectin 7 expression were associated with rapid recurrence rates and dismal prognoses in these 81 stage IV hypopharyngeal SCCs, a feature not observed with galectin 3 and one observed weakly, if at all, with galectin 1. CONCLUSIONS: These data suggest that the immunohistochemical determination of galectin 7 expression in the case of high-risk hypopharyngeal cancers is a meaningful tool to identify patients who should benefit from aggressive postsurgical adjuvant therapy after surgery, including not only radiotherapy, but also chemotherapy.
BACKGROUND: Eighty percent of hypopharyngeal squamous cell carcinomapatients have advanced stages (III and IV) of the disease, and biological markers are required to predict high-risk head and neck squamous cell carcinomapatients in need of highly aggressive treatments after surgery to improve the survival rate. We analyzed the potential prognostic value of galectin 7 in a series of 81 stage IV hypopharyngeal SCCs because galectin 7 is an emerging marker involved in the epidermal development of pluristratified epithelia and in epidermal cell migration. METHODS: The immunohistochemical expression of galectin 7 was determined on a series of 81 stage IV hypopharyngeal SCCs and was compared with that of galectins 1 and 3. RESULTS: High levels of galectin 7 expression were associated with rapid recurrence rates and dismal prognoses in these 81 stage IV hypopharyngeal SCCs, a feature not observed with galectin 3 and one observed weakly, if at all, with galectin 1. CONCLUSIONS: These data suggest that the immunohistochemical determination of galectin 7 expression in the case of high-risk hypopharyngeal cancers is a meaningful tool to identify patients who should benefit from aggressive postsurgical adjuvant therapy after surgery, including not only radiotherapy, but also chemotherapy.
Authors: Marilyne Labrie; Maria Vladoiu; Bruno G Leclerc; Andrée-Anne Grosset; Louis Gaboury; John Stagg; Yves St-Pierre Journal: PLoS One Date: 2015-07-13 Impact factor: 3.240
Authors: Elena Ermakova; Michelle C Miller; Irina V Nesmelova; Lara López-Merino; Manuel Alvaro Berbís; Yuri Nesmelov; Yaroslav V Tkachev; Laura Lagartera; Vladimir A Daragan; Sabine André; F Javier Cañada; Jesús Jiménez-Barbero; Dolores Solís; Hans-Joachim Gabius; Kevin H Mayo Journal: Glycobiology Date: 2013-01-31 Impact factor: 4.313
Authors: Nadège Kindt; Julie Preillon; Herbert Kaltner; Hans-Joachim Gabius; Dominique Chevalier; Alexandra Rodriguez; Bryon D Johnson; Véronique Megalizzi; Christine Decaestecker; Guy Laurent; Sven Saussez Journal: J Cancer Res Clin Oncol Date: 2013-01-25 Impact factor: 4.553